Actos (Pioglitazone) Cost in New Jersey

What Pioglitazone Costs at New Jersey Pharmacies in 2026

Generic pioglitazone is one of the least expensive branded-to-generic diabetes medications available at New Jersey pharmacies today. The average cash-pay price across NJ retail locations sits at approximately $15 per month for a 30-tablet supply of 15 mg or 30 mg tablets.

Brand vs. Generic Pricing

Brand-name Actos, manufactured by Takeda, carries a list price of roughly $60 per month. Since generic pioglitazone became available in 2012 after patent expiration, most prescriptions filled in New Jersey are dispensed as the generic. The price gap between brand and generic represents a 75% savings with no difference in bioequivalence, as confirmed by FDA Orange Book therapeutic equivalence ratings.

Regional Price Variation Within NJ

Pharmacy pricing in New Jersey varies by region. Urban pharmacies in Newark, Jersey City, and Trenton tend to price generics slightly lower due to higher volume and competition. Rural Sussex or Salem County pharmacies may charge $18 to $22 for the same 30-day supply. Warehouse clubs (Costco, Sam's Club) and grocery-chain pharmacies (ShopRite, Wegmans) typically offer the lowest per-unit pricing without requiring membership for pharmacy purchases under New Jersey consumer protection law.

How Pioglitazone Compares to Other Diabetes Drug Costs

For context, metformin (the first-line type 2 diabetes drug) costs $4 to $8 per month generically in NJ. Pioglitazone at $15 per month remains far cheaper than newer agents: brand GLP-1 receptor agonists like semaglutide (Ozempic) exceed $900 per month without insurance, and SGLT2 inhibitors like empagliflozin run $500+ at retail. Pioglitazone occupies a cost-effective second-line or add-on position for patients who need additional glycemic control beyond metformin [1].

New Jersey Medicaid Coverage for Pioglitazone

New Jersey Medicaid (NJ FamilyCare) covers pioglitazone with prior authorization. This means prescribers must document clinical necessity before the state plan reimburses the prescription.

Prior Authorization Requirements

The NJ Division of Medical Assistance and Health Services requires documentation that the patient has tried or cannot tolerate metformin before approving pioglitazone coverage. Standard PA criteria include: confirmed type 2 diabetes diagnosis, HbA1c above target on current therapy, and notation of any contraindications to preferred formulary alternatives. Approval typically takes 24 to 72 hours when submitted electronically through the state's preferred vendor, Magellan Rx Management.

Medicaid Managed Care Plans in NJ

Most NJ Medicaid beneficiaries are enrolled in managed care organizations (MCOs) including Aetna Better Health, Amerigroup, Horizon NJ Health, UnitedHealthcare Community Plan, and WellCare. Each MCO maintains its own preferred drug list (PDL), but all must cover pioglitazone per state mandate when PA criteria are met. Copays for generic pioglitazone under NJ Medicaid managed care range from $0 to $3 depending on the plan and income tier.

Off-Label NASH Use and Medicaid

Pioglitazone has strong evidence for non-alcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). The PIVENS trial (N=247) demonstrated that pioglitazone 30 mg daily produced histologic improvement in 34% of non-diabetic NASH patients versus 19% with placebo over 96 weeks [2]. NJ Medicaid does not routinely cover off-label NASH prescriptions without a specialist-initiated PA, but gastroenterologists and hepatologists in the state have reported successful approvals when liver biopsy or imaging confirms significant steatohepatitis.

Insurance Coverage Beyond Medicaid

Commercial insurance plans operating in New Jersey generally place generic pioglitazone on Tier 1 or Tier 2 of their formularies, resulting in copays between $0 and $20 per month.

Major NJ Insurers and Pioglitazone Tier Status

Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, lists generic pioglitazone as Tier 1 preferred generic with a typical $10 copay. AmeriHealth New Jersey and Oscar Health similarly classify it at the lowest generic tier. Cigna and Aetna commercial plans sold on the NJ exchange treat pioglitazone as Tier 1. Brand Actos, if specifically requested, falls to Tier 3 on most plans with copays of $40 to $60, making it cost-equivalent to paying cash for the generic.

Medicare Part D in New Jersey

Medicare Part D plans available to NJ residents universally cover generic pioglitazone. Under the 2025 Inflation Reduction Act cap (now fully implemented in 2026), Medicare beneficiaries pay no more than $2,000 total out-of-pocket per year for all Part D drugs combined. For a medication costing $15 per month, pioglitazone contributes minimally to that annual cap. Most Part D plans charge $0 to $5 for Tier 1 generics in the initial coverage phase.

Employer-Sponsored Plans

Large New Jersey employers (Johnson & Johnson, Prudential, Merck, BD) typically self-insure through national PBMs (Express Scripts, CVS Caremark, OptumRx). Generic pioglitazone universally sits at the lowest cost-sharing tier. Some high-deductible health plans (HDHPs) with HSAs require patients to pay full price until the deductible is met, but at $15 per month, the financial burden remains modest even pre-deductible.

Compounded Pioglitazone in New Jersey

Compounded pioglitazone is legal in New Jersey through licensed 503A pharmacies. These pharmacies can prepare custom pioglitazone formulations when a prescriber documents a patient-specific clinical need.

When Compounding Makes Sense

503A compounding applies when a patient requires a dose not commercially available (for example, 7.5 mg or 22.5 mg for patients titrating slowly due to fluid retention concerns), needs a different dosage form (liquid suspension for dysphagia patients), or has an allergy to an inactive ingredient in manufactured tablets. The cost for compounded pioglitazone from NJ 503A pharmacies varies by preparation complexity but can be comparable to or less than retail generic pricing.

Regulatory Framework

New Jersey Board of Pharmacy regulations permit 503A compounding under federal DQSA (Drug Quality and Security Act) guidelines. The pharmacy must hold a valid NJ compounding permit, compound pursuant to a valid patient-specific prescription, and use USP-grade pioglitazone powder from FDA-registered suppliers. 503B outsourcing facilities can also supply NJ prescribers with office-use quantities, though this pathway is less common for oral tablets.

Cost Considerations

Because generic pioglitazone tablets are already inexpensive ($15/month) and widely available in standard doses, compounding is rarely pursued for cost savings alone. The primary driver is clinical customization. Patients should verify their insurance covers compounded medications, as some plans exclude compounded drugs from formulary benefits.

Discount Programs and Savings Cards

Several programs reduce pioglitazone costs for New Jersey residents who are uninsured or underinsured.

Manufacturer and Generic Savings Programs

Takeda's patient assistance program historically covered brand Actos for qualifying uninsured patients, though its relevance has diminished as generics dominate the market. Generic manufacturers (Teva, Mylan/Viatris, Dr. Reddy's) do not typically offer individual savings cards for pioglitazone because the retail price is already low. However, pharmacy discount platforms (GoodRx, RxSaver, SingleCare) frequently display coupons bringing NJ prices to $8 to $12 for a 30-day supply at participating locations.

NJ Pharmaceutical Assistance Programs

New Jersey operates several state pharmaceutical assistance programs for residents:

• PAAD (Pharmaceutical Assistance to the Aged and Disabled): covers NJ residents 65+ or receiving Social Security disability with income below $37,581 (single) or $46,122 (married). Copay: $5 for generics.
• Senior Gold: for those slightly over PAAD income limits. Copay: $15 for generics.
• NJ FamilyCare (Medicaid expansion): covers adults under 138% FPL with minimal copays as described above.

These programs stack with federal subsidies. A 68-year-old NJ resident on both Medicare Part D and PAAD would pay effectively $0 for pioglitazone [3].

340B Program Access

Federally Qualified Health Centers (FQHCs) in New Jersey, including CAMcare Health Corporation (Camden), Newark Community Health Centers, and Zufall Health (Dover), participate in the 340B Drug Pricing Program. Patients seen at these centers access pioglitazone at significantly reduced prices regardless of insurance status. The 340B acquisition cost for pioglitazone is estimated at $2 to $4 per month.

Telehealth Prescribing in New Jersey

New Jersey permits telehealth prescribing of pioglitazone with no geographic or originating-site restrictions for the patient. The state's telehealth parity law (P.L. 2020, c.3, made permanent in 2021) requires insurers to cover telehealth visits at the same rate as in-person encounters.

How It Works

A prescriber licensed in New Jersey can evaluate a patient via synchronous audio-video visit, review labs (fasting glucose, HbA1c, liver function tests), and prescribe pioglitazone electronically to any NJ pharmacy. No in-person visit is required for initiation, though baseline labs must be obtained. The FDA prescribing information for pioglitazone recommends checking ALT before starting therapy and periodically thereafter due to the historical class concern with hepatotoxicity (traced to troglitazone, withdrawn in 2000, not pioglitazone).

Telehealth Platforms Serving NJ

Multiple telehealth platforms serve New Jersey residents for diabetes management, including endocrinology-focused services and primary care platforms. Patients can receive prescriptions for pioglitazone through these services, with electronic prescriptions sent to their preferred local pharmacy. Wait times for appointments are typically 1 to 3 days for established diabetes management visits.

Clinical Context: Why Pioglitazone Remains Relevant

Despite being a 25-year-old drug class, pioglitazone retains a meaningful role in type 2 diabetes and metabolic disease management, which justifies understanding its cost and access field.

Glycemic Efficacy and Durability

The ADOPT trial (N=4,360) demonstrated that rosiglitazone (a related thiazolidinedione) maintained glycemic control longer than metformin or glyburide monotherapy over 5 years [4]. Pioglitazone shares this durability advantage. HbA1c reductions of 1.0% to 1.5% are typical with pioglitazone 30 to 45 mg daily, and the effect persists without the secondary failure seen with sulfonylureas.

Cardiovascular and Hepatic Benefits

The PROactive trial (N=5,238) showed pioglitazone reduced the composite of all-cause mortality, non-fatal MI, and stroke by 16% (HR 0.84, P=0.027) in patients with type 2 diabetes and macrovascular disease [5]. For NASH/MASH, the PIVENS trial established pioglitazone as one of only two pharmacotherapies (alongside vitamin E) with randomized evidence of histologic improvement [2]. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance lists pioglitazone as a treatment option for biopsy-confirmed NASH regardless of diabetes status [6].

Known Risks and Monitoring

Pioglitazone carries labeled risks for fluid retention, weight gain (mean 2 to 4 kg), bone density reduction in postmenopausal women, and a possible signal for bladder cancer with prolonged use exceeding 2 years. The bladder cancer signal, initially identified in a Kaiser Permanente cohort, has been inconsistently replicated. A 2016 BMJ meta-analysis (N=1,010,920) found a modest relative risk of 1.14 (95% CI 1.04 to 1.24) for any bladder cancer exposure, but absolute risk remains low [7]. Prescribers in New Jersey follow standard monitoring: baseline and periodic liver function tests, assessment for heart failure symptoms (NYHA Class III/IV is contraindicated), and periodic urinalysis if long-term use is planned.

Step-by-Step: Getting the Lowest Price in NJ

For patients seeking to minimize out-of-pocket spending on pioglitazone in New Jersey, a systematic approach works best.

For Insured Patients

Confirm your plan's formulary tier for pioglitazone (generic). Request 90-day fills through mail-order pharmacy if your plan offers this option, as 90-day pricing typically saves 10% to 20% versus three separate 30-day fills. Horizon BCBS NJ and most commercial plans offer 90-day mail-order at 2x the 30-day copay.

For Uninsured Patients

Compare pricing across at least three pharmacies using a discount platform. Costco and Walmart pharmacies in NJ frequently have the lowest base pricing for generics. Apply for PAAD or Senior Gold if age/disability/income eligible. Visit an FQHC for both the prescribing visit and pharmacy fill to access 340B pricing.

For Medicare Beneficiaries

Under the $2,000 annual Part D cap, pioglitazone's contribution is negligible. If enrolled in both Part D and PAAD, the state program covers remaining cost-sharing. Choose a plan with $0 generic copay in the initial coverage phase during open enrollment.